Evidence map›Paper›PMID 21861666›Full record

ArticleBiomarkers in medicine2011

Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.

Gualberto Ruaño, David Villagra, Bonnie Szarek, Andreas Windemuth, Mohan Kocherla, Krystyna Gorowski, Christopher Berrezueta, Harold I Schwartz, John Goethe

Abstract read
In one paragraph

Article in Biomarkers in medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  2. Article
  3. Associations of antidepressants and antipsychotics with lipid parameters: DoJournal of psychopharmacology (Oxford, England) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Direct inhibition of retinoic acid catabolism by fluoxetine.Journal of neural transmission (Vienna, Austria : 1996) · 2015
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Gualberto RuañoGenomas Inc., Hartford, CT 06106, USA. gruano@harthosp.org
David Villagra
Bonnie Szarek
Andreas Windemuth
Mohan Kocherla
Krystyna Gorowski
Christopher Berrezueta
Harold I Schwartz
John Goethe
Hartford Hospital · USHartford Financial Services (United States)Genomas (United States) · US

Funding

DNA Diagnostics for Minimizing Metabolic Side-Effects of AntipsychoticsR44MH073291 · NIMH · GENOMAS, INC. · PI RUANO, GUALBERTO · 2007 to 2009
$1.5M
NIMH NIH HHS 2R44 MH073291NIMH NIH HHS R44 MH073291
6 · The paper itself

Abstract

aimsTo investigate associations between novel human cytochrome P450 (CYP450) combinatory (multigene) and substrate-specific drug metabolism indices, and elements of metabolic syndrome, such as low density lipoprotein cholesterol (LDLc), high density lipoprotein cholesterol (HDLc), triglycerides and BMI, using physiogenomic analysis.

methodsCYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications. Data analysis compared clinical measures of LDLc, HDLc, triglyceride and BMI with novel combinatory and substrate-specific CYP450 drug metabolism indices.

resultsWe found that a greater metabolic reserve index score is related to lower LDLc and higher HDLc, and that a greater metabolic alteration index score corresponds with higher LDLc and lower HLDc values. We also discovered that the sertraline drug-specific indices correlated with cholesterol and triglyceride values.

conclusionsOverall, we demonstrated how a multigene approach to CYP450 genotype analysis yields more accurate and significant results than single-gene analyses. Ranking the individual with respect to the population represents a potential tool for assessing risk of dyslipidemia in major depressive disorder patients who are being treated with psychotropics. In addition, the drug-specific indices appear useful for modeling a variable of potential relevance to an individual's risk of drug-related dyslipidemia.

Indexed as

AdolescentAdultAgedAryl Hydrocarbon HydroxylasesBiomarkersBody Mass IndexCholesterol, HDLCholesterol, LDLCohort StudiesCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 Enzyme SystemDyslipidemiasFemaleGenotypeAryl Hydrocarbon HydroxylasesBiomarkersCholesterol, HDLCholesterol, LDLCYP2C19 protein, humanCYP2C9 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 Enzyme SystemPsychotropic DrugsTriglycerides

Identifiers

PMID21861666
PMCPMC3225002
OpenAlexW1997098705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.